Head-To-Head Review: Sigyn Therapeutics (OTCMKTS:SIGY) and Ironwood Pharmaceuticals (NASDAQ:IRWD)

Sigyn Therapeutics (OTCMKTS:SIGY) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Volatility & Risk

Sigyn Therapeutics has a beta of -0.88, meaning that its stock price is 188% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Sigyn Therapeutics and Ironwood Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sigyn Therapeutics	0	0	0	0	0.00
Ironwood Pharmaceuticals	1	6	1	0	2.00

Ironwood Pharmaceuticals has a consensus price target of $5.34, indicating a potential upside of 84.78%. Given Ironwood Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than Sigyn Therapeutics.

Earnings & Valuation

This table compares Sigyn Therapeutics and Ironwood Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sigyn Therapeutics	N/A	N/A	-$3.34 million	($4.77)	-0.42
Ironwood Pharmaceuticals	$308.52 million	1.52	$880,000.00	($0.05)	-57.80

Ironwood Pharmaceuticals has higher revenue and earnings than Sigyn Therapeutics. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Sigyn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

10.0% of Sigyn Therapeutics shares are owned by institutional investors. 78.5% of Sigyn Therapeutics shares are owned by insiders. Comparatively, 12.7% of Ironwood Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Sigyn Therapeutics and Ironwood Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sigyn Therapeutics	N/A	N/A	-2,842.57%
Ironwood Pharmaceuticals	-2.25%	-2.46%	2.19%

Summary

Ironwood Pharmaceuticals beats Sigyn Therapeutics on 8 of the 13 factors compared between the two stocks.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.